Syndax Pharmaceuticals Inc (NASDAQ: SNDX) on Tuesday, soared 11.56% from the previous trading day, before settling in for the closing price of $13.76. Within the past 52 weeks, SNDX’s price has moved between $8.58 and $22.50.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -15.16%. The company achieved an average annual earnings per share of 18.19%. With a float of $83.34 million, this company’s outstanding shares have now reached $86.91 million.
The extent of productivity of a business whose workforce counts for 270 workers is very important to gauge.
Syndax Pharmaceuticals Inc (SNDX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Syndax Pharmaceuticals Inc is 3.25%, while institutional ownership is 120.68%. The most recent insider transaction that took place on Sep 08 ’25, was worth 2,582,021. In this transaction Chief Executive Officer of this company sold 157,307 shares at a rate of $16.41, taking the stock ownership to the 298,661 shares. Before that another transaction happened on Sep 08 ’25, when Company’s Director proposed sale 157,307 for $17.04, making the entire transaction worth $2,680,511.
Syndax Pharmaceuticals Inc (SNDX) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.1 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.23) by -0.87. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.54 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.19% per share during the next fiscal year.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Syndax Pharmaceuticals Inc (SNDX) is currently performing well based on its current performance indicators. A quick ratio of 4.42 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.62, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -1.46 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
The latest stats from [Syndax Pharmaceuticals Inc, SNDX] show that its last 5-days average volume of 3.97 million was superior to 2.36 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 44.78%.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 78.16%, which indicates a significant increase from 77.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.19 in the past 14 days, which was higher than the 0.76 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.32, while its 200-day Moving Average is $12.96. Now, the first resistance to watch is $16.38. This is followed by the second major resistance level at $17.42. The third major resistance level sits at $19.03. If the price goes on to break the first support level at $13.73, it is likely to go to the next support level at $12.12. The third support level lies at $11.08 if the price breaches the second support level.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
Market capitalization of the company is 1.32 billion based on 86,142K outstanding shares. Right now, sales total 23,680 K and income totals -318,760 K. The company made 37,960 K in profit during its latest quarter, and -71,850 K in sales during its previous quarter.
